

Dupilumab Therapy in Nephrotic Syndrome in Children

NCT07091175

Status	RECRUITING
Phase	Phase 2
Sponsor	National University Hospital, Singapore
Enrollment	66 participants

Key Eligibility Criteria

Inclusion (6)

- Age between 6 years old and 18 years old at the point of recruitment with idiopathic nephrotic syndrome with disease onset between 1-18 years old
 - Steroid-dependent disease or frequently relapsing disease prior to commencement of maintenance immunosuppression
 - On oral prednisolone +/- mycophenolate or levamisole only as maintenance therapy for 6 months or more, and with inadequate disease control or steroid toxicity on therapy
 - Nephrotic relapse or partial relapse (clinical or biochemical) within the last 1 year either unprovoked or during prednisolone wean, and which responded to increase in steroids
 - In complete remission at the time of recruitment
- ... and 1 more (see full listing online)

Exclusion (10)

- Pre-existing ophthalmological conditions except refractive errors, squint or mild cataract
 - Current symptoms of helminth infection or travel to endemic areas, unless helminth infection is excluded
 - eGFR (by Bedside Schwartz equation) ≤ 60 ml/min/1.73m²
 - Received Rituximab or other B-cell depleting agents within the last 1 year
 - Biopsy proven focal segmental glomerulosclerosis
- ... and 5 more (see full listing online)

Locations (2 total)

National University Hospital, Singapore, Singapore, Singapore
KK Women's and Children's Hospital, Singapore, Singapore, Singapore